Sera Prognostics Unveils Financial Results and Expands Growth Strategy for Maternal Health

Sera Prognostics Reports Fourth Quarter 2024 Financial Results

Sera Prognostics Inc., known as The Pregnancy Company®, has recently disclosed its financial results for the fourth quarter of 2024. This Salt Lake City-based firm, publicly traded under the Nasdaq symbol SERA, is dedicated to enhancing maternal and neonatal health by leveraging innovative pregnancy biomarker information for medical professionals and their patients.

Key Highlights from Recent Developments

On January 6, 2025, the Society for Maternal Fetal Medicine (SMFM) published an abstract detailing the primary outcomes of Sera’s study titled “Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcomes” (PRIME). The results were subsequently showcased at the SMFM 2025 Pregnancy Meeting, a prestigious conference addressing pregnancy complications. Dr. Brian Iriye, a maternal-fetal medicine expert, led the presentation, which highlighted critical findings, including a 25% reduction in the neonatal morbidity and mortality index (NMI) and an 18% decrease in hospital stays for neonates. Additionally, a broader intent-to-treat analysis showed a 20% reduction in NMI and a 22% decrease in NICU admissions.

Sera also acquired $57.5 million from a public follow-on offering in February 2025, which will further bolster their cash runway until 2028. This capital is earmarked for expansion of commercial efforts in selected U.S. regions, partnerships with payers and healthcare providers to enhance the adoption of Sera's flagship PreTRM test, and preparations for potential entry into the European market.

Zhenya Lindgardt, the President and CEO of Sera Prognostics, expressed gratitude towards investors for their support, emphasizing that the funds will assist in addressing the societal and healthcare burdens associated with premature births, ultimately improving outcomes for mothers and their babies.

Fourth Quarter 2024 Performance

For the fourth quarter of 2024, Sera reported revenues of $24,000, a decline from $41,000 in the fourth quarter of 2023. Total operating expenses rose to $9.4 million, reflecting a 6% increase from $8.9 million in the corresponding quarter last year as the company balanced cost management with strategic investments in product development and marketing initiatives.

Research and development expenses recorded a decrease to $3.1 million, down approximately 19% from the previous year’s fourth quarter. Conversely, selling, general and administrative expenses increased to $6.3 million compared to $5.0 million, as Sera focused spending on growth-driving activities. The net loss for the fourth quarter was $8.6 million, slightly higher than the $7.9 million loss reported in the prior year's quarter.

Financial Overview for the Full Year 2024

Looking at the complete year, Sera’s total revenue for 2024 amounted to $77,000, a significant drop from $306,000 in 2023. Operating expenses totaled $36.7 million, a decrease from $40.1 million in the previous year. R&D expenses also fell slightly to $14.7 million, down from $15.2 million, primarily due to reduced clinical study costs.

Selling, general, and administrative expenses for 2024 decreased markedly to $21.9 million compared to $24.7 million in 2023, reflecting measures taken to streamline operations. The overall net loss for 2024 was reported at $32.9 million, showing an improvement from the $36.2 million loss a year earlier.

By year-end, Sera had approximately $68.2 million in cash and securities. The recently raised capital is expected to strengthen the financial position of the company, allowing for enhanced adoption and commercialization of the PreTRM test.

Conference Call Details

Sera Prognostics hosted a conference call and live webcast to discuss the operational highlights and financial results for the fourth quarter and full year 2024. For those interested in listening to the call, they can access the live audio via the company’s investor relations page.

About Sera Prognostics

Sera Prognostics is dedicated to transforming maternity care through data-driven insights into pregnancy health. The company's flagship PreTRM® test serves as an early predictor of the risk of preterm birth, enabling proactive interventions for at-risk mothers. As preterm birth is a leading cause of neonatal complications, Sera aims to help healthcare providers improve outcomes for both mothers and their newborns, thus significantly impacting public health costs related to premature births.

In conclusion, Sera Prognostics is positioned for growth with robust financial support and a strong commitment to advancing maternal and neonatal health. As it sets forth into future endeavors, its innovative approaches and impactful studies place it at the forefront of crucial healthcare initiatives.